

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Assignment of Equal and Undivided Right, Title & Interest
CONVEYING PARTY DATA	
Name	Execution Date
AMYLIN PHARMACEUTICALS, INC.	10/25/2010
RECEIVING PARTY DATA	
Name:	Eli Lilly and Company
Street Address:	Lilly Corporate Center
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46285
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	12298933
Application Number:	60799913
CORRESPONDENCE DATA	
Fax Number:	(858)552-1936
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	858 309-7497
Email:	patents@amylin.com
Correspondent Name:	AMYLIN PHARMACEUTICALS, INC.
Address Line 1:	9360 Towne Centre Drive
Address Line 2:	Intellectual Property Group
Address Line 4:	San Diego, CALIFORNIA 92121
ATTORNEY DOCKET NUMBER:	0234US-PRO1, UTL1
NAME OF SUBMITTER:	Renee Zavala
Total Attachments: 1 source=Assignment-50-Lilly#page1.tif	

CH \$80.00 12298933

501334667

PATENT
REEL: 025214 FRAME: 0788

ASSIGNMENT


WHEREAS, **Amylin Pharmaceuticals, Inc.** is the owner of the entire right, title and interest in US Application No. 60/799,913 filed May 12, 2006; US Application No. 12/298,933 filed January 7, 2009; and European Application No. 07777061.8, by virtue of an Assignment from the Inventors recorded in the US Patent Office on September 5, 2006, at Reel 018204, Frame 0151.

WHEREAS, **Eli Lilly and Company**, a corporation of the State of Indiana, with a principal place of business at Lilly Corporate Center, Indianapolis, Indiana, 46285 is desirous of acquiring *an equal and undivided* right, title, and interest in and to US Application No. 60/799,913 filed May 12, 2006; US Application No. 12/298,933 filed January 7, 2009; and European Application No. 07777061.8;

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, **Amylin Pharmaceuticals, Inc.** hereby grants to **Eli Lilly and Company** *an equal and undivided* right, title, and interest in and to US Application No. 60/799,913 filed May 12, 2006; US Application No. 12/298,933 filed January 7, 2009; and European Application No. 07777061.8; and to any and all patents issuing therefrom, including reissues, reexaminations, and extensions thereof; and to any and all continuing applications, including divisional, continuation, continuation-in-part, and substitute applications, and any and all patents issuing therefrom, including reissues, reexaminations, and extensions thereof.

The *equal and undivided* right, title, and interest granted by **Amylin Pharmaceuticals, Inc.** to **Eli Lilly and Company** are to be viewed in accordance with the Collaboration Agreement between **Amylin Pharmaceuticals, Inc.** and **Eli Lilly and Company** dated September 19, 2002, as amended.

IN TESTIMONY WHEREOF, **Amylin Pharmaceuticals, Inc.** has hereto set its seal.



Harry J. Leonhardt
Vice President, Legal, Governance and Corporate Secretary

Date: October 25, 2010